These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8818647)

  • 21. Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies.
    Li X; Gervaix A; Kang D; Law P; Spector SA; Ho AD; Wong-Staal F
    Gene Ther; 1998 Feb; 5(2):233-9. PubMed ID: 9578843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retroviral delivery and anti-HIV testing of hammerhead ribozymes.
    Cagnon L; Rossi J
    Methods Mol Biol; 1997; 74():451-7. PubMed ID: 9204460
    [No Abstract]   [Full Text] [Related]  

  • 23. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
    Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
    Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new reporter system for detection of retroviral infection.
    Planelles V; Haislip A; Withers-Ward ES; Stewart SA; Xie Y; Shah NP; Chen IS
    Gene Ther; 1995 Aug; 2(6):369-76. PubMed ID: 7584111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term RNase P-mediated inhibition of HIV-1 replication and pathogenesis.
    Hnatyszyn H; Spruill G; Young A; Seivright R; Kraus G
    Gene Ther; 2001 Dec; 8(24):1863-71. PubMed ID: 11821940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
    Mautino MR; Morgan RA
    Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel ribozyme target site located in the HIV-1 nef open reading frame.
    Larsson S; Hotchkiss G; Su J; Kebede T; Andäng M; Nyholm T; Johansson B; Sönnerborg A; Vahlne A; Britton S; Ahrlund-Richter L
    Virology; 1996 May; 219(1):161-9. PubMed ID: 8623525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MLV-derived retroviral vectors selective for CD4-expressing cells and resistant to neutralization by sera from HIV-infected patients.
    Stitz J; Steidl S; Merget-Millitzer H; König R; Müller P; Nocken F; Engelstädter M; Bobkova M; Schmitt I; Kurth R; Buchholz CJ; Cichutek K
    Virology; 2000 Feb; 267(2):229-36. PubMed ID: 10662618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1.
    Yamada O; Yu M; Yee JK; Kraus G; Looney D; Wong-Staal F
    Gene Ther; 1994 Jan; 1(1):38-45. PubMed ID: 7584058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer.
    Li Y; Starr SE; Lisziewicz J; Ho WZ
    Gene Ther; 2000 Feb; 7(4):321-8. PubMed ID: 10694813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS.
    Ngok FK; Mitsuyasu RT; Macpherson JL; Boyd MP; Symonds GP; Amado RG
    Methods Mol Biol; 2004; 252():581-98. PubMed ID: 15017082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved CD4 lymphocyte outgrowth in response to effective antiretroviral therapy.
    Merrill DP; Martinez-Picado J; Tremblay C; Sax PE; Boswell SL; Wong JT; D'Aquila RT; Walker BD; Hirsch MS
    J Infect Dis; 1999 Feb; 179(2):345-51. PubMed ID: 9878017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical protocol. A phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects.
    MacGregor RR
    Hum Gene Ther; 2001 Nov; 12(16):2028-9. PubMed ID: 11727736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model.
    ter Brake O; Legrand N; von Eije KJ; Centlivre M; Spits H; Weijer K; Blom B; Berkhout B
    Gene Ther; 2009 Jan; 16(1):148-53. PubMed ID: 18668146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low autocrine interferon beta production as a gene therapy approach for AIDS: Infusion of interferon beta-engineered lymphocytes in macaques chronically infected with SIVmac251.
    Gay W; Lauret E; Boson B; Larghero J; Matheux F; Peyramaure S; Rousseau V; Dormont D; De Maeyer E; Le Grand R
    Retrovirology; 2004 Sep; 1():29. PubMed ID: 15447786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
    Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
    J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conservation of a hairpin ribozyme sequence in HIV-1 is required for efficient viral replication.
    Yamada O; Kraus G; Sargueil B; Yu Q; Burke JM; Wong-Staal F
    Virology; 1996 Jun; 220(2):361-6. PubMed ID: 8661387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autocrine interferon-beta synthesis for gene therapy of HIV infection: increased resistance to HIV-1 in lymphocytes from healthy and HIV-infected individuals.
    Vieillard V; Lauret E; Maguer V; Jacomet C; Rozenbaum W; Gazzolo L; De Maeyer E
    AIDS; 1995 Nov; 9(11):1221-8. PubMed ID: 8561974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical characterization of an anti-tat ribozyme for therapeutic application.
    Wang L; Witherington C; King A; Gerlach WL; Carr A; Penny R; Cooper D; Symonds G; Sun LQ
    Hum Gene Ther; 1998 Jun; 9(9):1283-91. PubMed ID: 9650613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.